MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12185-022-03488-5

Медицинская библиотека · International journal of hematology · 2022

Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies.

Oliveira Ana C, Roncero Josep Maria, Ferrá Christelle, Do Nascimento Janilson, Rodriguez-Luaces Marta, Encuentra Maite, Domingo-Domenech Eva, López Patricia, Gallardo David, Ribera Josep Maria, Sarrá Josep, Sureda Anna, González-Barca Eva

СтатьяПеревод пока не подготовлен

Аннотация

Fludarabine-cyclophosphamide-rituximab (FCR) has been the gold standard front-line treatment for fit CLL patients until novel agent's introduction. Decision between either time-limited FCR or "endless" Bruton's tyrosine kinase inhibitor (BTKi) therapy may be difficult in fit IGHV-mutated-non-TP53 cases. We describe the outcomes after front-line FCR in 110 CLL patients from 5 centres in Catalonia, Spain, over a period of more than 10 years. ORR was 96.3% and CR 74.5%. Median second-treatment free survival (TFS1) was 6.2 years and median OS was 10.8 years. 50 (45.5%) patients required a subsequent therapy. Median third-treatment free survival was better for BTKi than for chemotherapy ± antiCD20 strategies (not reached vs 3.1 years, p = 0.003). Only 50 (45.5%) patients completed 6 cycles of FCR, and the main reason for discontinuation was cytopenia 29 (26.4%). 15 (13.6%) patients developed a second cancer, and 5 (4.5%) patients experienced a Richter's transformation (RT). At the end of follow-up, 50 (45.5%) patients remained in CR. Response rates, TFS1, OS, RT, and second cancers did not differ between patients treated with 6 vs 4 cycles of FCR. In conclusion, front-line FCR treatment leads to very long CR in almost half of patients, and BTKi yields excellent outcomes in relapsed patients.

Для цитирования: Oliveira Ana C, Roncero Josep Maria, Ferrá Christelle, Do Nascimento Janilson, Rodriguez-Luaces Marta, Encuentra Maite, Domingo-Domenech Eva, López Patricia, Gallardo David, Ribera Josep Maria, Sarrá Josep, Sureda Anna, González-Barca Eva. Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies.. International journal of hematology. 2022. DOI: 10.1007/s12185-022-03488-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.